Proto Axiom is a biotech incubator that provides early-stage funding and preclinical research support to Australian startups, ensuring that local intellectual property in drug development and medical devices remains in Australia. By addressing the lack of domestic preclinical expertise, Proto Axiom facilitates the transition of scientific breakthroughs from proof-of-concept to commercial success, enhancing the economic impact of Australian innovations.
Funding
$30M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Australian biotech startups often struggle to translate early-stage research into commercially viable products due to a lack of local preclinical expertise and funding. This results in valuable intellectual property being transferred overseas, hindering the growth of the domestic biotech industry and limiting economic benefits for Australia.
Solution
Proto Axiom provides early-stage funding and comprehensive preclinical research support to Australian biotech startups, enabling them to develop and retain their intellectual property within the country. By offering a combination of investment and hands-on incubation services, Proto Axiom bridges the gap between scientific discovery and commercialization, accelerating the development of innovative drugs and medical devices. The incubator's approach ensures that Australian research breakthroughs are nurtured locally, fostering a thriving biotech ecosystem and maximizing the economic impact of Australian innovation.
Target Audience
Proto Axiom primarily targets early-stage Australian biotech startups and researchers with promising innovations in drug development and medical devices.
Features
- Early-stage funding for promising biotech startups
- Access to preclinical research facilities and expertise
- Commercialization guidance and support
- Portfolio construction of innovative biotech businesses
- On-shoring of scientific capacity to keep IP in Australia